213 related articles for article (PubMed ID: 29027612)
41. A Truncating Germline Mutation of
He H; Li W; Comiskey DF; Liyanarachchi S; Nieminen TT; Wang Y; DeLap KE; Brock P; de la Chapelle A
Thyroid; 2020 Feb; 30(2):204-213. PubMed ID: 31928178
[No Abstract] [Full Text] [Related]
42. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
43.
Brock P; Sevigny M; Liyanarachchi S; Comiskey DF; Li W; Saarinen S; Yilmaz AS; Nieminen AI; Ringel MD; Peltomäki P; Ollila S; Nieminen TT
Thyroid; 2024 May; 34(5):575-582. PubMed ID: 38062777
[No Abstract] [Full Text] [Related]
44. A Germline
Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
[TBL] [Abstract][Full Text] [Related]
45. Familial non-medullary thyroid cancer: a critical review.
Capezzone M; Robenshtok E; Cantara S; Castagna MG
J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
[TBL] [Abstract][Full Text] [Related]
46.
Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
[TBL] [Abstract][Full Text] [Related]
47. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?
Shifrin AL; Xenachis C; Fay A; Matulewicz TJ; Kuo YH; Vernick JJ
Surgery; 2009 Dec; 146(6):998-1005. PubMed ID: 19958926
[TBL] [Abstract][Full Text] [Related]
48. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
49. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
50. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
51. Identification of
Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
[No Abstract] [Full Text] [Related]
52. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
53. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
54. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
[TBL] [Abstract][Full Text] [Related]
55. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
[TBL] [Abstract][Full Text] [Related]
56. Is Familial Nonmedullary Thyroid Cancer A More Aggressive Type of Thyroid Cancer?
Muallem Kalmovich L; Jabarin B; Koren S; Or K; Marcus E; Tkacheva I; Benbassat C; Steinschneider M
Laryngoscope; 2021 Feb; 131(2):E677-E681. PubMed ID: 32761812
[TBL] [Abstract][Full Text] [Related]
57. Results of Screening in Familial Non-Medullary Thyroid Cancer.
Klubo-Gwiezdzinska J; Yang L; Merkel R; Patel D; Nilubol N; Merino MJ; Skarulis M; Sadowski SM; Kebebew E
Thyroid; 2017 Aug; 27(8):1017-1024. PubMed ID: 28657510
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening.
Grani G; Lamartina L; Montesano T; Giacomelli L; Biffoni M; Trulli F; Filetti S; Durante C
Thyroid; 2022 Nov; 32(11):1392-1401. PubMed ID: 36097761
[No Abstract] [Full Text] [Related]
59. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
60. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
